Allergan posted better-than-expected second quarter earnings of
$1.51 per share, surpassing the Zacks Consensus Estimate of $1.44.
While earnings climbed 23.8% year over year, revenues increased
16.1% to $1,854.5 million, above the Zacks Consensus Estimate of
$1,720 million. Allergan upped its 2014 EPS guidance again to $6.20
$6.25. Over the next five years, Allergan expects double-digit
sales growth and compounded annual earnings growth of more than
20%. Allergan's restructuring plans, which involve cutting its
workforce by 13% and reducing R&D and other expenditure, will
aid the bottom line. While we remain optimistic about Allergan's
growth prospects, we are moving back to a Neutral recommendation as
we believe the current share price reflects the positive factors.
We expect near-term investor focus to remain on Valeant's efforts
to acquire Allergan.
Headquartered in Irvine, CA, Allergan, Inc., a global
multi-specialty pharmaceutical company, develops and commercializes
innovative products for eye care, neurological, medical aesthetics,
medical dermatology, breast aesthetics, urological and other
specialty markets. In addition to its discovery-to-development
research programs, Allergan has global marketing and sales
capabilities in over 100 countries.
The company operates through two business segments: specialty
pharmaceuticals and medical devices. While the specialty
pharmaceuticals segment includes ophthalmic, skin care as well as
other prescription and over-the-counter dermatological products,
Botox and urologics products, the medical devices segment includes
breast implantation and dermal fillers.
The medical devices segment was created through the company's
Mar 2006 acquisition of global healthcare company Inamed
Corporation. The specialty pharmaceuticals segment contributed
about 84.7% to total revenues in 2013, with sales coming in at $5.3
billion. Botox, a key product in this segment, posted sales of
$1.98 billion in 2013. Sales from the medical devices segment came
in at $858.5 million in 2013.
In Dec 2013, Allergan sold its obesity intervention business
which had been performing badly over the past few years.
In Dec 2012, the company bought a privately held company,
SkinMedica, Inc. to acquire the latter's topical aesthetics skin
care business. In Mar 2013, Allergan acquired Map Pharmaceuticals,
which is now a wholly owned subsidiary of Allergan.
Allergan is currently being pursued by Valeant which is looking
to acquire the company for a combination of 0.83 of Valeant common
shares and $72 in cash per share.
Allergan, Inc. (AGN): Read the Full Research
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ALLERGAN INC (AGN): Free Stock Analysis Report
To read this article on Zacks.com click here.